子宫内膜癌新分子分型的影响:一项法国队列研究
该法国队列研究纳入2014年1月1日至2020年12月31日在克雷泰伊市间医院中心治疗的80例子宫内膜癌患者,评估ESGO 2020分子分型指南对辅助治疗、手术策略和生存的影响。21例(26.3%)被重新分类,9例(11.3%)按2020 ESGO分类属于过度治疗,无患者被治疗不足。p53突变组复发率最高(37.5%,3/8),POLE突变组无复发。
要点
- 分子分型使26.3%(21/80)的患者被重新分类到更准确的预后组。
- 按2020 ESGO分类,11.3%(9/80)患者属于过度治疗,无患者治疗不足。
- p53突变组复发率37.5%(3/8),POLE突变组无复发。
核心结论
- 约四分之一患者通过分子诊断和最新ESGO指南被重新分类到更准确的预后组,可能减少辅助治疗的使用以降低发病率。
研究设计与样本
- 法国克雷泰伊市间医院中心(CHIC)前瞻性维护数据库的队列研究,纳入2014年1月1日至2020年12月31日治疗的子宫内膜癌患者80例。
- 对所有术后样本复核组织学亚型、肌层浸润、细胞核分级和淋巴血管栓塞,行p53、MLH1、MSH2、MSH6、PMS2免疫组化及系统性POLE测序。
主要发现
- 80例中NSMP占70%(n=56),MSI占13.75%(n=11),p53突变占10%(n=8),POLEmut占6.25%(n=5)。
- 21例(26.3%)使用最新ESGO分类被重新分类,低危或晚期/转移性疾病患者未被分子分析重新分类。
- 初始中高危患者重新分类影响最大:10/23重新分类为中危,4/23重新分类为低危。
- 9例(11.3%)按2020 ESGO分类属于过度治疗:低危组6例(4例接受阴道近距离放疗,2例接受外照射放疗),中危组3例(3例接受外照射放疗,1例接受化疗)。
- p53突变组复发率37.5%(3/8),POLE突变组无复发。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the potential impact of the latest ESGO guidelines for endometrial cancer with molecular classification on the management strategy in a French cohort. METHODS: All patients treated between January 1st, 2014 and December 31, 2020 for an endometrial cancer at the Centre Hospitalier Intercommunal de Créteil (CHIC, FRANCE) were selected from our prospectively maintained database. All postoperative samples were reviewed to confirm histological subtype, myometrial infiltration, cytonuclear grade and presence of lymphovascular emboli. Analysis of p53, MLH1, MSH2, MSH6, PMS2 genes was performed by immunohistochemistry first then a systematic POLE sequencing was performed to identify gene mutation. The impact of the latest ESGO 2020 guidelines was assessed regarding adjuvant therapy, surgical strategy, and survival. RESULTS: Eighty patients were analyzed, including 70% NSMP (n = 56), 13.75% MSI (n = 11), 10% p53 mutated (n = 8) and 6.25% POLEmut (n = 5). A total of 21 patients (26.3%) were reclassified using the latest ESGO classification. Patients classified at low risk or with advanced / metastatic disease were not reclassified using molecular analysis. Molecular analysis and the latest ESGO classification had the most important impact on patients initially classified at intermediate - high risk that were reclassified in intermediate (10/23) and in low (4/23) risk. Nine patients (11.3%) were overtreated according to the 2020 ESGO classification: six patients in the low - risk group (4 received vaginal brachytherapy and 2 external radiotherapy) and three in the intermediate risk group (3 received external irradiation and 1 received chemotherapy). None of the patients in our cohort would have been undertreated using the 2020 ESGO classification. Patients within the p53 mutated group were the most likely to experience recurrence (37.5%, 3/8) and none of the patients POLE mutated recurred. CONCLUSION: Around one in 4 patients were reclassified in a more accurate prognostic group using molecular diagnosis and the latest ESGO guidelines which could decrease the use of adjuvant therapies to spare morbidity.
引用
- Benichou J, Schwall C, Sastre-Garau X, et al. Impact of the new molecular classification of endometrial cancer: A French cohort study. Gynecol Oncol. 2022. PMID: 35843738. doi:10.1016/j.ygyno.2022.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。